Biotech Start-up / Early Stage CEO Forum - 2020 Programme
The prevailing theme during this CEO Forum is survivability and thrivability during COVID-19.
A unique, powerful and valuable space for the candid sharing of experience between 25 of the sector’s emerging and innovative pre-series A Biotech executives. Like-minded Executives are joined by 2 appropriate and value-matched industry stakeholders and partners to provide expertise, experience and best practice on strategic areas of focus. Case studies will also be delivered by a number of executives in the room who have enjoyed success or navigated key challenges in their pursuit of company growth.
A pre-registration only, exclusive hollow square forum where all participants are active discussants. This CEO forum is delivered in a virtual setting via Zoom.
Attendance is FREE, however executives must satisfy a number of key criteria points outlined during registration.
Qualifier: Company executives must be pre-series A and from a US-based therapeutic-indication Biotech company
Date: Wednesday, 7th October 2020
Timings: 11:00AM - 1:00PM EDT / 08:00AM - 10.00AM PDT
Co-Hosted by:
Moderator – Sarah Solomon, Partner, Technology & Life Sciences Group, Goodwin Procter
Ms. Solomon represents biotechnology, pharmaceutical, medical device and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as joint research and development agreements, co-commercialization agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, supply, distribution, clinical trial, university and academic licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and structured M&A transactions). Ms. Solomon also counsels clients in connection with international transactions in North America, South America, Europe and Asia.
11.00 – Realizing the value of a therapeutic asset
11.20 – CEO Case Study - Company creation, ideation, a $33m Series A finance raising and collaboration during COVID-19
Shawn Leland, Founder and Chief Business Officer, Elevation Oncology
Shawn M. Leland is the Founder of Elevation Oncology and currently serves as its Chief Business Officer overseeing all day-to-day operations. Shawn brings over a decade of experience in medical affairs and business development for the pharmaceutical/biotech industry, with a focus on building collaborations to realize the full potential of targeted and personalized therapeutics. Shawn has been involved in global transactions totaling more than $450 million in upfront payments and milestone payments at Eli Lilly, ARIAD Pharmaceuticals, Argos Therapeutics and Verastem Oncology. Shawn has also served as an expert strategic consultant for Catenion providing guidance on portfolio management for pharmaceutical/biotech companies.
11.40 – Making the most of your FDA Interactions to aid preclinical or other preparatory studies / initial clinical development strategies
Alex Varond, Partner, Technology and Life Sciences Group, Goodwin Procter
Alexander Varond is a Partner in Goodwin’s Technology & Life Sciences group. Mr. Varond advises drug, biotech, and device clients on a wide range of FDA regulatory matters. He has extensive experience in medical device and drug development, Hatch-Waxman patent and exclusivity issues, and regulatory strategy. Mr. Varond also counsels on advertising and promotional issues, defends companies during civil and criminal investigations on a variety of issues, including off-label promotion and GMPs, and regularly advises on corporate transactions.
12.00 – CEO Case Study - Preclinical stage partnering rationale, strategies and structures
Dr. Reddy has over 15 years of progressive leadership in life science research, business management and product development. He has led biotech start-ups in agricultural biotechnology, therapeutics and medical devices, across the R&D-commercial continuum. As an Entrepreneur in Residence at the Florida Institute for Commercialization of Public Research, he has worked with numerous start-up companies as an advisor, provided interim management support and served on their Boards to ensure successful commercialization of technology licensed from public research institutions in Florida. Previously, he was the Director of Program Management at Nanotherapeutics, Inc., where he has managed several multi-million-dollar NIH/BARDA grants and contracts. He received his Ph.D. from the University of Idaho and his M.B.A. from the University of Florida.
12.20 – General Discussion
Discussion to include but not limited to:
Moderator – Sarah Solomon, Partner, Technology & Life Sciences Group, Goodwin Procter
Ms. Solomon represents biotechnology, pharmaceutical, medical device and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as joint research and development agreements, co-commercialization agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, supply, distribution, clinical trial, university and academic licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and structured M&A transactions). Ms. Solomon also counsels clients in connection with international transactions in North America, South America, Europe and Asia.
13.00 – Forum Close
Current CEO participants include:
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
RetroTherapy Inc. |  |
 |
 |
Somagevity Inc. | Sunshine Bio Inc. |
 |
 |
 |
For enquiries contact:
Matt Pullan, SVP, Business Development
matt@lsxleaders.com
